Safety Evaluation of Bowel Cleansing Regimen for PillCam® COLON 2 Capsule Endoscopy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Given Imaging Ltd.
ClinicalTrials.gov Identifier:
NCT01575093
First received: March 11, 2012
Last updated: July 4, 2012
Last verified: July 2012

March 11, 2012
July 4, 2012
March 2012
June 2012   (final data collection date for primary outcome measure)
To evaluate the safety of a bowel preparation regimen comprised of Sulfate free Polyethylene glycol electrolyte lavage solution (SF-PEG) plus SUPREP oral sulfate solution as a "booster", in adult subjects. [ Time Frame: Latest blood test conducted (i.e. 24 hours after suppository or seven days after procedure) ] [ Designated as safety issue: Yes ]
Safety will be evaluated by number of Adverse Events and percentage of subjects with clinically siginifcant change in serum chemistry test.
Same as current
Complete list of historical versions of study NCT01575093 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety Evaluation of Bowel Cleansing Regimen for PillCam® COLON 2 Capsule Endoscopy
Not Provided

This study is designed to evaluate the safety of a preparation regimen for PillCam® Colon 2 Capsule Endoscopy.

The preparation regimen used for the PillCam® Colon 2 procedure consists of several colon cleansing materials.

Different combinations of the above regimen were tested and evaluated for safety by monitoring of adverse events in multiple clinical studies, with more than 1000 subjects enrolled to date. No Serious Adverse Events related to the preparation were noted.

In this study, each subject will be required to undergo serum chemistry tests (blood tests) at several time points to evaluate the safety of the regimen.

No capsule ingestion is involved.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Healthy Volunteers
Other: The preparation regimen
Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
June 2012
June 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject is between 50 - 75 years of age.
  2. Subject is healthy without any known disease, or any current symptoms of any disease or other abnormal condition.
  3. Subject received an explanation about the nature of the study and agrees to provide written informed consent.
  4. Subject has normal serum chemistry tests at baseline.

Exclusion Criteria:

  1. Subject has any allergy or other known contraindication to the medications used in the study.
  2. Subject with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters.
  3. Subject has Type 1 or Type II Diabetes.
  4. Subject has any condition which precludes compliance with study instructions.
  5. Women who are either pregnant or nursing at the time of screening, or are of child-bearing potential and do not practice medically acceptable methods of contraception.
  6. Subject suffers from life threatening conditions.
  7. Concurrent participation in another clinical trial using any investigational drug or device.
Both
50 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01575093
MA-112
No
Given Imaging Ltd.
Given Imaging Ltd.
Not Provided
Principal Investigator: PANKAJ K. KASHYAP, M.D. Pinnacle Research Group, LLC
Given Imaging Ltd.
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP